Company Overview

Modular Medical, Inc. is a medical device company focused on the development of a next-generation insulin delivery system for people living with diabetes, particularly those with Type 1 diabetes and insulin-dependent Type 2 diabetes. The company operates within the medical devices and diabetes care industries, with its core mission centered on simplifying insulin pump therapy to improve usability, accessibility, and patient adherence. Its primary product candidate is a wearable insulin pump designed to reduce complexity relative to traditional pump systems while maintaining clinically relevant dosing precision.

The company’s strategic positioning emphasizes ease of use, affordability, and a streamlined design intended to broaden adoption among patients who may be underserved by existing pump technologies. Modular Medical traces its origins to technology development efforts aimed at rethinking insulin delivery ergonomics and cost structure. Over time, it transitioned into a publicly listed entity to fund late-stage development, regulatory preparation, and commercialization efforts for its insulin pump platform.

Business Operations

Modular Medical’s operations are centered on research and development, regulatory preparation, and early-stage commercialization planning for its insulin pump system. The company generates no material commercial revenue as of the most recent public filings and is primarily funded through equity financing and capital markets activity. Its core business activities include device engineering, clinical testing, quality systems development, and engagement with regulatory authorities in the United States.

The company’s operational assets include proprietary pump design technology, intellectual property related to insulin delivery mechanisms, and in-house product development capabilities. Modular Medical does not currently report broad international commercial operations and has not disclosed material joint ventures or revenue-generating partnerships. Manufacturing is expected to rely on a combination of internal oversight and third-party suppliers, consistent with common practices among early-stage medical device companies.

Strategic Position & Investments

Modular Medical’s strategic direction is focused on advancing its insulin pump through regulatory pathways, achieving U.S. market clearance, and preparing for commercial launch. Growth initiatives primarily involve completing development milestones, scaling manufacturing readiness, and building distribution and reimbursement strategies within the diabetes care ecosystem. The company’s strategy prioritizes differentiation through simplicity, with the goal of appealing to patients and clinicians seeking alternatives to more complex pump systems.

The company has not disclosed major acquisitions or a diversified investment portfolio. Its investments are concentrated in internal product development, intellectual property protection, and operational infrastructure. Modular Medical is not currently active in unrelated emerging technologies and remains tightly focused on insulin delivery as its core and sole strategic area.

Geographic Footprint

Modular Medical is headquartered in the United States and conducts the majority of its operations domestically. Its primary geographic focus is the U.S. market, reflecting the regulatory pathway, reimbursement environment, and size of the insulin-dependent diabetes population. Research, development, and corporate functions are all U.S.-based according to public disclosures.

International operations are limited, and the company has not reported material revenue, subsidiaries, or manufacturing facilities outside the United States. While future expansion into international markets may be contemplated following regulatory approval and commercialization, current public information indicates that Modular Medical’s operational and strategic footprint remains primarily domestic.

Leadership & Governance

Modular Medical is led by an executive team with experience in medical devices, healthcare operations, and corporate management. The leadership team is responsible for guiding the company through late-stage development, regulatory engagement, and preparation for commercialization, with an emphasis on disciplined capital allocation and product-focused execution.

Key executives include:

• Jeb Besser – President & Chief Executive Officer
• Brian Faulkner – Chief Financial Officer

Public disclosures emphasize a leadership philosophy centered on patient-centric design, operational efficiency, and long-term value creation through focused execution. Information regarding additional executive officers or board committee leadership beyond publicly named roles is limited; data inconclusive based on available public sources.